Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:ADCY3-UBR4

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: ADCY3-UBR4
	FusionPDB ID: 2235
	FusionGDB2.0 ID: 2235
		Hgene	Tgene
	Gene symbol	ADCY3	UBR4
	Gene ID	114	23352
	Gene name	adenylate cyclase 8	ubiquitin protein ligase E3 component n-recognin 4
	Synonyms	AC8\|ADCY3\|HBAC1	RBAF600\|ZUBR1\|p600
	Cytomap	8q24.22	1p36.13
	Type of gene	protein-coding	protein-coding
	Description	adenylate cyclase type 8ATP pyrophosphate-lyase 8HEL-S-172mPadenylate cyclase 8 (brain)adenylate cyclase type VIIIadenylyl cyclase 8adenylyl cyclase-8, brainca(2+)/calmodulin-activated adenylyl cyclaseepididymis secretory sperm binding protein Li	E3 ubiquitin-protein ligase UBR4N-recognin-4RING-type E3 ubiquitin transferase UBR4retinoblastoma-associated factor 600-like proteinretinoblastoma-associated factor of 600 kDazinc finger UBR1-type protein 1
	Modification date	20200313	20200313
	UniProtAcc	O60266 Main function of 5'-partner protein: FUNCTION: Catalyzes the formation of the signaling molecule cAMP in response to G-protein signaling. Participates in signaling cascades triggered by odorant receptors via its function in cAMP biosynthesis. Required for the perception of odorants. Required for normal sperm motility and normal male fertility. Plays a role in regulating insulin levels and body fat accumulation in response to a high fat diet. {ECO:0000250\|UniProtKB:Q8VHH7}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000260600, ENST00000405392, ENST00000450524,	ENST00000375218, ENST00000375224, ENST00000375225, ENST00000429347, ENST00000467272, ENST00000543981, ENST00000375217, ENST00000375226, ENST00000375254, ENST00000375267,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	7 X 6 X 5=210	14 X 16 X 7=1568
	# samples	7	16
	** MAII score	log2(7/210*10)=-1.58496250072116 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(16/1568*10)=-3.29278174922785 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: ADCY3 [Title/Abstract] AND UBR4 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: ADCY3 [Title/Abstract] AND UBR4 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	ADCY3(25043593)-UBR4(19436958), # samples:1
Anticipated loss of major functional domain due to fusion event.	ADCY3-UBR4 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ADCY3-UBR4 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ADCY3-UBR4 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ADCY3-UBR4 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ADCY3-UBR4 seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF. ADCY3-UBR4 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. ADCY3-UBR4 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	UBR4	GO:0006511	ubiquitin-dependent protein catabolic process	23932781

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:25043593/chr1:19436958)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across ADCY3 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across UBR4 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000260600	ADCY3	chr2	25043593	-	ENST00000375217	UBR4	chr1	19436958	-	8090	4104	852	7763	2303
ENST00000260600	ADCY3	chr2	25043593	-	ENST00000375226	UBR4	chr1	19436958	-	8090	4104	852	7763	2303
ENST00000260600	ADCY3	chr2	25043593	-	ENST00000375267	UBR4	chr1	19436958	-	8153	4104	852	7826	2324
ENST00000260600	ADCY3	chr2	25043593	-	ENST00000375254	UBR4	chr1	19436958	-	8090	4104	852	7763	2303

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000260600	ENST00000375217	ADCY3	chr2	25043593	-	UBR4	chr1	19436958	-	0.006088731	0.99391127
ENST00000260600	ENST00000375226	ADCY3	chr2	25043593	-	UBR4	chr1	19436958	-	0.006088731	0.99391127
ENST00000260600	ENST00000375267	ADCY3	chr2	25043593	-	UBR4	chr1	19436958	-	0.005064915	0.9949351
ENST00000260600	ENST00000375254	ADCY3	chr2	25043593	-	UBR4	chr1	19436958	-	0.006088731	0.99391127

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ADCY3-UBR4

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
ADCY3	chr2	25043593	UBR4	chr1	19436958	4104	1084	SRMESTGVMGNIQASSLQYEMLLLTD

Top

Potential FusionNeoAntigen Information of ADCY3-UBR4 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

ADCY3-UBR4_25043593_19436958.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:01	IQASSLQY	0.9997	0.665	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:25	IQASSLQY	0.9945	0.7873	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:01	NIQASSLQY	0.9955	0.688	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:08	QASSLQYEM	0.9953	0.8675	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:01	QASSLQYEM	0.9888	0.9033	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:25	NIQASSLQY	0.98	0.7842	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:08	NIQASSLQY	0.9783	0.7883	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:02	NIQASSLQY	0.9775	0.8061	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:05	QASSLQYEM	0.9752	0.6569	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:03	QASSLQYEM	0.9751	0.9151	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:01	NIQASSLQY	0.9395	0.7729	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:04	QASSLQYEM	0.8119	0.9669	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:02	QASSLQYEM	0.8119	0.9669	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:04	IQASSLQY	0.9924	0.6462	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:05	IQASSLQY	0.9501	0.7075	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-C03:19	QASSLQYEM	0.9995	0.9719	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:21	NIQASSLQY	0.9792	0.7788	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-C12:12	QASSLQYEM	0.969	0.8858	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:05	NIQASSLQY	0.9604	0.6956	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:31	NIQASSLQY	0.9387	0.7028	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-C03:14	QASSLQYEM	0.8922	0.9814	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-C08:03	QASSLQYEM	0.8757	0.9803	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:12	QASSLQYEM	0.8119	0.9669	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:27	IQASSLQY	0.9997	0.6611	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:135	IQASSLQY	0.9997	0.6623	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:125	IQASSLQY	0.9997	0.665	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:33	IQASSLQY	0.9997	0.665	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:34	IQASSLQY	0.9997	0.665	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:50	IQASSLQY	0.9995	0.7792	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:35	IQASSLQY	0.9991	0.5946	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:12	IQASSLQY	0.9988	0.6116	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:53	IQASSLQY	0.9976	0.5983	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:39	IQASSLQY	0.9949	0.6057	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:54	IQASSLQY	0.9944	0.5635	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:20	IQASSLQY	0.9546	0.8222	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:28	IQASSLQY	0.9411	0.8318	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B18:04	IQASSLQY	0.8474	0.7978	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B48:02	IQASSLQY	0.6081	0.8053	11	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-C03:03	QASSLQYEM	0.9996	0.9688	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-C03:04	QASSLQYEM	0.9996	0.9688	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-C03:02	QASSLQYEM	0.9995	0.9536	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:27	NIQASSLQY	0.9958	0.7023	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:34	NIQASSLQY	0.9955	0.688	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:125	NIQASSLQY	0.9955	0.688	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:33	NIQASSLQY	0.9955	0.688	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:135	NIQASSLQY	0.9948	0.7088	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:11	QASSLQYEM	0.9946	0.9029	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-C03:06	QASSLQYEM	0.993	0.9711	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:50	NIQASSLQY	0.9921	0.8534	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-C16:04	QASSLQYEM	0.9911	0.9667	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:77	QASSLQYEM	0.9888	0.9033	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:23	QASSLQYEM	0.9882	0.9213	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:11	NIQASSLQY	0.9866	0.6111	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:08	NIQASSLQY	0.9841	0.6204	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:17	QASSLQYEM	0.9803	0.8444	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:30	QASSLQYEM	0.9803	0.8444	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:11	NIQASSLQY	0.9793	0.7632	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-C12:03	QASSLQYEM	0.9772	0.971	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:39	NIQASSLQY	0.9769	0.5932	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:43	NIQASSLQY	0.9739	0.6171	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:13	QASSLQYEM	0.9737	0.9201	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:08	QASSLQYEM	0.9685	0.7959	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:43	QASSLQYEM	0.9633	0.8052	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:20	NIQASSLQY	0.9623	0.8062	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:12	NIQASSLQY	0.9519	0.7521	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:23	NIQASSLQY	0.9412	0.7596	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-C16:01	QASSLQYEM	0.94	0.97	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:77	NIQASSLQY	0.9395	0.7729	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:20	NIQASSLQY	0.9389	0.8313	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:28	NIQASSLQY	0.9327	0.8124	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-C16:02	QASSLQYEM	0.8913	0.9916	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:24	QASSLQYEM	0.8861	0.8722	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-C08:01	QASSLQYEM	0.8757	0.9803	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:22	QASSLQYEM	0.8205	0.5265	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:09	QASSLQYEM	0.8119	0.9669	12	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B35:24	NIQASSLQY	0.8109	0.7216	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B18:04	NIQASSLQY	0.3488	0.7808	10	19
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:73	IQASSLQYEM	0.988	0.849	11	21
ADCY3-UBR4	chr2	25043593	chr1	19436958	4104	HLA-B15:30	IQASSLQYEM	0.984	0.7448	11	21

Top

Potential FusionNeoAntigen Information of ADCY3-UBR4 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of ADCY3-UBR4

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
3213	GVMGNIQASSLQYE	ADCY3	UBR4	chr2	25043593	chr1	19436958	4104

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ADCY3-UBR4

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	3213	GVMGNIQASSLQYE	-5.6364	-5.6364
HLA-A24:02	5HGA	3213	GVMGNIQASSLQYE	-9.18993	-9.18993

Top

Vaccine Design for the FusionNeoAntigens of ADCY3-UBR4

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
ADCY3-UBR4	chr2	25043593	chr1	19436958	10	19	NIQASSLQY	AACATTCAGGCAAGTAGCCTGCAGTAT
ADCY3-UBR4	chr2	25043593	chr1	19436958	11	19	IQASSLQY	ATTCAGGCAAGTAGCCTGCAGTAT
ADCY3-UBR4	chr2	25043593	chr1	19436958	11	21	IQASSLQYEM	ATTCAGGCAAGTAGCCTGCAGTATGAAATG
ADCY3-UBR4	chr2	25043593	chr1	19436958	12	21	QASSLQYEM	CAGGCAAGTAGCCTGCAGTATGAAATG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of ADCY3-UBR4

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
Non-Cancer	ADCY3-UBR4	chr2	25043593	ENST00000260600	chr1	19436958	ENST00000375217	ERR188387

Top

Potential target of CAR-T therapy development for ADCY3-UBR4

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

ADCY3

chr2:25043593

chr1:19436958

ENST00000260600

105_125

1084

1145.0

Transmembrane

Helical

Hgene

ADCY3

chr2:25043593

chr1:19436958

ENST00000260600

139_159

1084

1145.0

Transmembrane

Helical

Hgene

ADCY3

chr2:25043593

chr1:19436958

ENST00000260600

173_193

1084

1145.0

Transmembrane

Helical

Hgene

ADCY3

chr2:25043593

chr1:19436958

ENST00000260600

226_246

1084

1145.0

Transmembrane

Helical

Hgene

ADCY3

chr2:25043593

chr1:19436958

ENST00000260600

381_401

1084

1145.0

Transmembrane

Helical

Hgene

ADCY3

chr2:25043593

chr1:19436958

ENST00000260600

633_653

1084

1145.0

Transmembrane

Helical

Hgene

ADCY3

chr2:25043593

chr1:19436958

ENST00000260600

664_684

1084

1145.0

Transmembrane

Helical

Hgene

ADCY3

chr2:25043593

chr1:19436958

ENST00000260600

708_728

1084

1145.0

Transmembrane

Helical

Hgene

ADCY3

chr2:25043593

chr1:19436958

ENST00000260600

754_774

1084

1145.0

Transmembrane

Helical

Hgene

ADCY3

chr2:25043593

chr1:19436958

ENST00000260600

775_795

1084

1145.0

Transmembrane

Helical

Hgene

ADCY3

chr2:25043593

chr1:19436958

ENST00000260600

80_100

1084

1145.0

Transmembrane

Helical

Hgene

ADCY3

chr2:25043593

chr1:19436958

ENST00000260600

833_853

1084

1145.0

Transmembrane

Helical

Tgene

UBR4

chr2:25043593

chr1:19436958

ENST00000375218

850_870

213.0

Transmembrane

Helical

Tgene

UBR4

chr2:25043593

chr1:19436958

ENST00000375218

993_1013

213.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene	Hchr	Hbp	Henst	Tgene	Tchr	Tbp	Tenst	DeepLoc result
ADCY3	chr2	25043593	ENST00000260600	UBR4	chr1	19436958	ENST00000375217
ADCY3	chr2	25043593	ENST00000260600	UBR4	chr1	19436958	ENST00000375267

Top

Related Drugs to ADCY3-UBR4

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to ADCY3-UBR4

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)